( lly significantreduction in plasma glu...)First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes,Health

About Type 2 Diabetes

Type 2 diabetes is the most common form of diabetes, accounting for approximately 90-95 percent of diabetes cases. Having Type 2 diabetes increases the risk of many serious complications, including heart disease or stroke, high blood pressure, amputation (particularly legs), blindness, nerve damage, and kidney failure. The risk of stroke and the rate of deaths due to heart disease are two to four times higher among people with diabetes, and about 65 percent of deaths among people with diabetes are due to heart disease and stroke.

The A1C test (also known as hemoglobin A1C) is used primarily to monitor the glucose control of diabetics over time. The goal of those with diabetes is to keep their blood glucose levels as close to normal as possible. This helps to minimize the complications caused by chronically elevated glucose levels, such as progressive damage to body organs like the kidneys, eyes, cardiovascular system, and nerves. The A1C test gives a picture of the average amount of glucose in the blood over the last few months. It can help a patient and his doctor know if the measures they are taking to control the patient's diabetes are successful or need to be adjusted.

About Dapagliflozin

Dapagliflozin (previously referred to as BMS-512148) is an investigational drug under development by Bristol-Myers Squibb and AstraZeneca. It is being studied as a once-daily oral antidiabetic. The compound has a novel proposed mechanism of action, selectively inhibiting sodium glucose cotransporter 2 (SGLT2) versus SGLT1, decreasing reabsorption of glucose by the kidneys without affecting SGLT1 in the GI tract. Dapagliflozin has a C-glucoside chemical structure, which prolon
'"/>